Table 1.
Baseline Characteristics of Study Subjects by TDF Treatment Status
| TDF Treatment | ||||
|---|---|---|---|---|
| Treated (n = 233) | Untreated (n = 126) | |||
| No. | % | No. | % | |
| Sex | ||||
| Male | 174 | 75 | 60 | 48 |
| Female | 59 | 25 | 66 | 52 |
| Liver cirrhosis | ||||
| Decompensated cirrhosis | 82 | 35 | 0 | 0 |
| No/compensated cirrhosis | 151 | 65 | 126 | 100 |
| Hepatitis B e-antigen | ||||
| Negative | 153 | 66 | 110 | 87 |
| Positive | 77 | 33 | 5 | 4 |
| Missing | 3 | 1 | 11 | 9 |
| Hepatitis C antibody | ||||
| Negative | 212 | 91 | 109 | 86 |
| Positive | 5 | 2 | 5 | 4 |
| Missing | 16 | 7 | 12 | 10 |
| Hepatitis D antibody | ||||
| Negative | 221 | 95 | 126 | 100 |
| Positive | 7 | 3 | 0 | 0 |
| Missing | 5 | 2 | 0 | 0 |
| Median | IQR (Range) | Median | IQR (Range) | |
|---|---|---|---|---|
| Follow-up time (mo) | 51 | 27–72 (3–75) | 69 | 66–72 (57–75) |
| Age (y) | 33 | 26–40 (18–65) | 33 | 27–41 (18–61) |
| Mean | SD (Range) | Mean | SD (Range) | |
|---|---|---|---|---|
| BMI, kg/m2 | 21.4 | 3.8 (14–35) | 24.1 | 4.4 (16–40) |
| Missing | 5 | 2 | ||
| HBV DNA viral load, log10 IU/mL | 4.9 | 2.2 (1–9) | 3.2 | 1.2 (1–8) |
| Missing | 19 | 2 | ||
| Platelet count, × 109/L | 239 | 120 (61–637) | 291 | 71 (56–507) |
| Missing | 16 | 9 | ||
| Liver stiffness, kPa | 20.8 | 19 (3.4–75) | 5.4 | 1.4 (3–12) |
| Missing | 18 | 12 | ||
| Alanine aminotransferase, U/L | 57 | 72 (11–493) | 26 | 15 (9–105) |
| Missing | 0 | 0 | ||
| Aspartate aminotransferase, U/L | 53 | 57 (10–576) | 26 | 12 (10–95) |
| Missing | 0 | 0 | ||
| Creatinine, μmol/L | 0.8 | 0.2 (0.1–1.4) | 0.8 | 0.2 (0.4–2.0) |
| Missing | 0 | 0 | ||
| Creatinine clearance, mL/min | 115 | 57 (52–783) | 117 | 42 (35–411) |
| Missinga | 4 | 0 |
Abbreviations: BMI, body mass index; TDF, tenofovir disoproxil fumarate.
a
Baseline body weight, needed to calculate creatinine clearance, was missing in 4 patients.